Abstract
RNA interference (RNAi) is a natural mechanism in cells that suppresses or silences the expression of aberrant or foreign genes. This activity is being developed as a potential antiviral therapeutic strategy. Studies in vitro, and some in vivo, appear to show the feasibility of using RNAi to treat virus infection. Therapeutic use of RNAi seems to be promising when directed against viruses that cause localized acute infections in accessible target cells. Therapeutic strategies using RNAi against viruses that cause chronic infections, such as HIV, hepatitis B virus, or hepatitis C virus, are more difficult to design, but studies have begun to address identifiable problems. Two clinical trials using RNAi have recently been initiated—one phase II trial against respiratory syncytial virus and a phase I trial against HIV. It will be of much interest to see whether nucleic acid therapies can offer another route to treating viral infection.
Article PDF
Similar content being viewed by others
References and Recommended Reading
Rossi JJ: Interference and inhibition: RNAi mechanisms and therapeutic prospects. Presented at the 4th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention. Sydney, Australia; July 22–25, 2007.
Li M, Li H, Rossi JJ: RNAi in combination with a ribozyme and TAR decoy for treatment of HIV infection in hematopoietic cell gene therapy. Ann N Y Acad Sci 2006, 1082:172–179.
Robbins MA, Li M, Leung I, et al.: Stable expression of shRNAs in human CD34+ progenitor cells can avoid induction of interferon responses to siRNAs in vitro. Nat Biotechnol 2006, 24:566–571.
Michienzi A, Castanotto D, Lee N, et al.: RNA-mediated inhibition of HIV in a gene therapy setting. Ann N Y Acad Sci 2003, 1002:63–71.
Scherer L, Rossi JJ, Weinberg MS: Progress and prospects: RNA-based therapies for treatment of HIV infection. Gene Ther 2007, 14:1057–1064.
Yeung ML, Bennasser Y, Le SY, Jeang KT: siRNA, miRNA and HIV: promises and challenges. Cell Res 2005, 15:935–946.
Wilson JF: Gene therapy yields to RNA interference. Ann Intern Med 2005, 143:161–164.
Amado RG, Mitsuyasu RT, Rosenblatt JD, et al.: Antihuman immunodeficiency virus hematopoietic progenitor cell-delivered ribozyme in a phase I study: myeloid and lymphoid reconstitution in human immunodeficiency virus type-1-infected patients. Hum Gene Ther 2004, 15:251–262.
Levine BL, Humeau LM, Boyer J, et al.: Gene transfer in humans using a conditionally replicating lentiviral vector. Proc Natl Acad Sci U S A 2006, 103:17372–17377.
Tijsterman M, Ketting RF, Plasterk RH: The genetics of RNA silencing. Annu Rev Genet 2002, 36:489–519.
Leonard JN, Schaffer DV: Antiviral RNAi therapy: emerging approaches for hitting a moving target. Gene Ther 2006, 13:532–540.
Check E: Pioneering HIV treatment would use interference and gene therapy. Nature 2005, 437:601.
Grimm D, Kay MA: Therapeutic short hairpin RNA expression in the liver: viral targets and vectors. Gene Ther 2006, 13:563–575.
Dykxhoorn DM, Lieberman J: Knocking down disease with siRNAs. Cell 2006, 126:231–235.
Dykxhoorn DM, Lieberman J: Silencing viral infection. PLoS Med 2006, 3:e242.
de Fougerolles A, Vornlocher HP, Maraganore J, Lieberman J: Interfering with disease: a progress report on siRNA-based therapeutics. Nat Rev Drug Discov 2007, 6:443–453.
Zamore PD, Aronin N: siRNAs knock down hepatitis. Nat Med 2003, 9:266–267.
Boden D, Pusch O, Lee F, et al.: Human immunodeficiency virus type 1 escape from RNA interference. J Virol 2003, 77:11531–11535.
Das AT, Brummelkamp TR, Westerhout EM, et al.: Human immunodeficiency virus type 1 escapes from RNA interference-mediated inhibition. J Virol 2004, 78:2601–2605.
Westerhout EM, Ooms M, Vink M, et al.: HIV-1 can escape from RNA interference by evolving an alternative structure in its RNA genome. Nucleic Acids Res 2005, 33:796–804.
Wilson JA, Richardson CD: Hepatitis C virus replicons escape RNA interference induced by a short interfering RNA directed against the NS5b coding region. J Virol 2005, 79:7050–7058.
Palliser D, Chowdhury D, Wang QY, et al.: An siRNA-based microbicide protects mice from lethal herpes simplex virus 2 infection. Nature 2006, 439:89–94.
Bitko V, Musiyenko A, Shulyayeva O, Barik S: Inhibition of respiratory viruses by nasally administered siRNA. Nat Med 2005, 11:50–55.
Ge Q, Filip L, Bai A, et al.: Inhibition of influenza virus production in virus-infected mice by RNA interference. Proc Natl Acad Sci U S A 2004, 101:8676–8681.
Tompkins SM, Lo CY, Tumpey TM, Epstein SL: Protection against lethal influenza virus challenge by RNA interference in vivo. Proc Natl Acad Sci U S A 2004, 101:8682–8686.
Li BJ, Tang Q, Cheng D, et al.: Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in Rhesus macaque. Nat Med 2005, 11:944–951.
Kumar P, Lee SK, Shankar P, Manjunath N: A single siRNA suppresses fatal encephalitis induced by two different flaviviruses. PLoS Med 2006, 3:e96.
Morrissey DV, Blanchard K, Shaw L, et al.: Activity of stabilized short interfering RNA in a mouse model of hepatitis B virus replication. Hepatology 2005, 41:1349–1356.
Morrissey DV, Lockridge JA, Shaw L, et al.: Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat Biotechnol 2005, 23:1002–1007.
Chen CC, Ko TM, Ma HI, et al.: Long-term inhibition of hepatitis B virus in transgenic mice by double-stranded adeno-associated virus 8-delivered short hairpin RNA. Gene Ther 2007, 14:11–19.
McCaffrey AP, Nakai H, Pandey K, et al.: Inhibition of hepatitis B virus in mice by RNA interference. Nat Biotechnol 2003, 21:639–644.
Ying RS, Zhu C, Fan XG, et al.: Hepatitis B virus is inhibited by RNA interference in cell culture and in mice. Antiviral Res 2007, 73:24–30.
Klein C, Bock CT, Wedemeyer H, et al.: Inhibition of hepatitis B virus replication in vivo by nucleoside analogues and siRNA. Gastroenterology 2003, 125:9–18.
Merl S, Michaelis C, Jaschke B, et al.: Targeting 2A protease by RNA interference attenuates coxsackieviral cytopathogenicity and promotes survival in highly susceptible mice. Circulation 2005, 111:1583–1592.
Xiong D, Lee GH, Badorff C, et al.: Dystrophin deficiency markedly increases enterovirus-induced cardiomyopathy: a genetic predisposition to viral heart disease. Nat Med 2002, 8:872–877.
Fechner H, Pinkert S, Wang X, et al.: Coxsackievirus B3 and adenovirus infections of cardiac cells are efficiently inhibited by vector-mediated RNA interference targeting their common receptor. Gene Ther 2007, 14:960–971.
Jopling CL, Yi M, Lancaster AM, et al.: Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. Science 2005, 309:1577–1581.
Song E, Lee SK, Wang J, et al.: RNA interference targeting Fas protects mice from fulminant hepatitis. Nat Med 2003, 9:347–351.
Niu XY, Peng ZL, Duan WQ, et al.: Inhibition of HPV 16 E6 oncogene expression by RNA interference in vitro and in vivo. Int J Gynecol Cancer 2006, 16:743–751.
Yokota T, Iijima S, Kubodera T, et al.: Efficient regulation of viral replication by siRNA in a non-human primate surrogate model for hepatitis C. Biochem Biophys Res Commun 2007, 361:294–300.
Novina CD, Murray MF, Dykxhoorn DM, et al.: siRNA-directed inhibition of HIV-1 infection. Nat Med 2002, 8:681–686.
Qin XF, An DS, Chen IS, Baltimore D: Inhibiting HIV-1 infection in human T cells by lentiviral-mediated delivery of small interfering RNA against CCR5. Proc Natl Acad Sci U S A 2003, 100:183–188.
Anderson J, Akkina R: HIV-1 resistance conferred by siRNA cosuppression of CXCR4 and CCR5 coreceptors by a bispecific lentiviral vector. AIDS Res Ther 2005, 2:1.
Bennasser Y, Le SY, Benkirane M, Jeang KT: Evidence that HIV-1 encodes an siRNA and a suppressor of RNA silencing. Immunity 2005, 22:607–619.
Cave E, Weinberg MS, Cilliers T, et al.: Silencing of HIV-1 subtype C primary isolates by expressed small hairpin RNAs targeted to gag. AIDS Res Hum Retroviruses 2006, 22:401–410.
Lee SK, Dykxhoorn DM, Kumar P, et al.: Lentiviral delivery of short hairpin RNAs protects CD4 T cells from multiple clades and primary isolates of HIV. Blood 2005, 106:818–826.
Sabariegos R, Gimenez-Barcons M, Tapia N, et al.: Sequence homology required by human immunodeficiency virus type 1 to escape from short interfering RNAs. J Virol 2006, 80:571–577.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Huang, D.D. The potential of RNA interference-based therapies for viral infections. Curr HIV/AIDS Rep 5, 33–39 (2008). https://doi.org/10.1007/s11904-008-0006-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11904-008-0006-4